The Spy Next Door?
Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations
For decades, the U.S. has fostered international research collaborations with scientists in other countries, encouraging openness in hopes of better...
Online Exclusives
Trump Administration Considering Democratic Senator’s Drug Pricing Proposal
In early July, Senate Finance Committee Chairman Chuck Grassley (R-IA) met with Republican committee members to discuss a potential agreement that he and Sen....
Former VP Biden Wants to Usher in The Next Generation of...
Democratic presidential candidate and former Vice President Joe Biden released his health care plan, which primarily builds on the Affordable Care Act (ACA) while...
News
From the Blood Journals
Equal Access to Treatment Erases Difference in Outcomes Between White and...
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma
According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
Multimedia
Pulling Back the Curtain: Anna Schuh, MD, PhD
In more from our interview with Anna Schuh, MD, PhD, she shares her experiences volunteering with hematology patients in Tanzania.
Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia
Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...
Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.
Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma
Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
On Location
AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420,...
Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis
In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of...
Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia
Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to...
Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas
In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half...
Evaluating Rozanolixizumab in Primary Immune Thrombocytopenia
Rozanolixizumab, at doses ranging from 4 to 15 mg/kg, induced platelet responses in patients with...
Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia
Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced...
Latest Headlines
ASH Directions
New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
Next ASH Congressional Fellow Is Bound for Capitol Hill
Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the...
2020 Brings New Editor-in-Chief for ASH Clinical News, and more
Learn About Legislation and Health Policy from the ASH Advocacy Leadership Institute!
This October marks the ninth annual ASH Advocacy Leadership Institute (ALI): An opportunity...
Steven Rosenberg Receives Szent-Györgyi Prize, FDA Names Elizabeth Jungman Head of Regulatory Policy, and...
Steven A. Rosenberg Receives Szent-Györgyi Prize
The National Foundation for Cancer Research has awarded Steven A. Rosenberg, MD, PhD, the 2019 Szent-Györgyi Prize for Progress...
Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More
Remembering Milton H. Freedman (1919 – 2019)
Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21,...
Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more
Remembering Arthur Rosenberg (1935 – 2018)
Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
The Spy Next Door?
Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations
For decades, the U.S. has fostered international research collaborations with...
In Myeloma, New Drugs, Skyrocketing Price Tags
In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...
Resurrecting the House Call
New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction
Physician home visits have become a thing of the past: Nearly a century...
